Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology (Chinese Academy of Sciences) reported dual small-molecule-controlled CRISPR genome editing systems—PRINCE and Little Prince—that can be switched on by drug inducers and largely kept silent without them. The work, published in Science Translational Medicine, focuses on improving temporal control of editing activity in living tissues. The platform uses drug-triggered genome editing to reduce unintended activity when the inducer is absent, addressing a recurring challenge for therapeutic CRISPR approaches. “Switchable” designs are intended to make editing more predictable and safer by aligning biological activity with dosing. The study’s results add another control layer to the pipeline of gene-editing technologies aimed at limiting off-target risks and improving controllability in vivo. It positions small-molecule governance as a practical lever for clinicians evaluating CRISPR-based therapies.